Los Gatos, California – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, today announced the successful completion of patient enrollment for the company’s VENOS-2 early feasibility study (NCT06712251). This multi-center study is being performed under an Investigational […]
Peripheral/Endo
SonoVascular wins Angel Capital Association 2025 Luis Villalobos Award
CHAPEL HILL, N.C., April 16, 2025 /PRNewswire/ — SonoVascular, Inc., a clinical stage medical device company focused on bringing to market its SonoThrombectomy™ System, a safer and more effective treatment of venous thromboembolism (VTE), was awarded the Angel Capital Association’s 2025…
FluidForm Bio™ Advances Vascularized Tissue Engineering with New FRESH™ 3D Bioprinting Breakthrough
WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) — FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced a major advancement in vascularized tissue engineering. A newly published study in ACS Biomaterials Science & Engineering demonstrates how FRESH™ 3D bioprinting, combined with sacrificial gelatin microparticles, significantly enhances cell viability in thick tissue constructs by improving nutrient diffusion and enabling scalable perfusion strategies.
Cagent Vascular Initiates Patient Enrollment in the Serranator® vs. POBA OCT Study at Columbia University Medical Center
Study Seeks to Confirm Benefits of Cagent’s Unique Serration Balloon Angioplasty Technology vs. Plain Old Balloon Angioplasty (POBA) in treating Peripheral Artery Disease (PAD) in Below-the-Knee Arteries. WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, announced its 1st patient enrollment of the […]
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
Successful robotic navigation was achieved in every case and met the primary endpoint of the study
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
MIAMI, March 26, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time.
Evident Vascular Raises Series B Financing to Advance AI-Powered Intravascular Ultrasound Platform Technology
Funding to accelerate development of next-generation intravascular ultrasound platform and support FDA clearance for U.S. market launch SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc., a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today announced the successful closing of its Series B financing with new […]
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International. Twelve-month results from the randomized arm of the WAVE trial are scheduled for presentation at the Society of Interventional Radiology’s 50th Annual Scientific Meeting in Nashville, TN. The podium presentation is scheduled for March 30, 2025, during the late-breaking trials session.
Imperative Care Expands Symphony Precision Thrombectomy Portfolio with Purpose-Built Design for the Treatment of Venous Thrombosis
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82cm version of its Symphony™ 16F Catheter, the company’s latest innovation designed to elevate care for patients with venous thrombosis, a serious condition caused by a blood clot forming in the veins of […]
Okami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery Catheter
ALISO VIEJO, Calif., March 24, 2025 /PRNewswire/ — Okami Medical announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the SENDERO MAX Delivery Catheter. This milestone expands Okami’s embolization portfolio, which includes the…